Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
NEW YORK (Reuters Health) – While oxybutynin is often used prophylactically to reduce irritative urinary symptoms related to intravesical bacillus Calmette-Guerin (BCG) therapy for bladder cancer, it actually…
NEW YORK (Reuters Health) – In patients with liver cancer related to hepatitis B virus (HBV) infection, giving nucleoside analogues after curative surgery appears to reduce the risk…
Almost 15 percent of the general population is affected by migraine headaches. Previous research has shown that patients experiencing migraines had a higher risk of developing small lesions…
NEW YORK (Reuters Health) – Patients with myelodysplastic syndrome (MDS) who are treated with azacitidine before allogeneic stem-cell transplantation fare as well as patients receiving standard pre-transplant induction chemotherapy, according to a French…
NEW YORK (Reuters Health) – Reduced-intensity conditioning that includes two daily 2.5-mg/kg doses of antithymocyte globulin before allogeneic stem-cell transplantation for hematologic malignancy significantly reduces graft-versus-host disease (GvHD)…
NEW YORK (Reuters Health) – Patients with myelodysplastic syndrome (MDS) who are treated with azacitidine before allogeneic stem-cell transplantation fare as well as patients receiving standard pre-transplant induction…
One of the most common dietary supplements taken by many American adults is a daily multivitamin. Recently, a new study found that men over 50 who took a…
NEW YORK (Reuters Health) – Even the best strategies for selectively testing colorectal CRC tumors for mismatch repair (MMR) gene mutations will miss 5% to 15% of Lynch…
NEW YORK (Reuters Health) – The use of tumor necrosis factor alpha inhibitors (TNF-I) therapy for various immune-mediated chronic inflammatory diseases does not increase the risk of cancer,…
